Table 2. Most common AEs (>10 % of patients overall) observed in 16 patients during the combination of gefitinib and radiotherapy (weeks 1-11).

Toxicity	Number of patients N (%)	AEs N
Gastrointestinal disorders	13 (81.3%)	34
Nausea	7 (43.8%)	9
Diarrhea	6 (37.5%)	7
Esophagitis	4 (25.0%)	4
Vomiting	4 (25.0%)	6
Dysphagia	2 (12.5%)	2
Stomatitis	2 (12.5%)	2
Skin disorders	13 (81.3%)	16
Dermatitis	5 (31.3%)	5
Rash	4 (25.0%)	4
Erythema	3 (18.8%)	3
General disorders	9 (56.3%)	21
Chest pain	4 (25.0%)	4
Fatigue	3 (18.8%)	5
Asthenia	2 (12.5%)	3
Mucosal inflammation	2 (12.5%)	2
Pyrexia	2 (12.5%)	4
Respiratory disorders	8 (50.0%)	12
Cough	4 (25.0%)	4
Investigations	7 (43.8%)	12
ALT increased	3 (18.8%)	3
AST increased	3 (18.8%)	3
Weight decreased	2 (12.5%)	2
Metabolism and nutrition disorders	6 (37.5%)	8
Anorexia	4 (25.0%)	4
Dehydration	2 (12.5%)	2
Nervous system disorders	5 (31.3%)	7
Headache	2 (12.5%)	4
Vascular disorders	5 (31.3%)	6
Hypotension	3 (18.8%)	3
Procedural complications	4 (25.0%)	4
Radiodermitis	2 (12.5%)	2
Cardiac disorders	3 (18.8%)	5
Eye disorders	3 (18.8%)	3
Infections	3 (18.8%)	3
Psychiatric disorders	2 (12.5%)	2

AEs: adverse events, N: number of, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase.